Therapeutic CD8 + T cell tissue retention and immunomodulation during ART interruption fail to prevent SIV rebound
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2501037122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von M Betina Pampena und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104. Hauptthemen laut MEDLINE: Simian Acquired Immunodeficiency Syndrome, CD8-Positive T-Lymphocytes, Simian Immunodeficiency Virus, Immunomodulation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIAID NIH HHS, Tissue Reservoirs Scientific Working Group in the Penn Center for AIDS Research, NCI NIH HHS.
Abstract (Originalsprache)
A primary obstacle for HIV elimination is the long-term viral reservoir in lymphoid tissues (LT) that can cause rebound viremia if therapy is stopped. Cytotoxic CD8 + T cells are critical for control of HIV and Simian immunodeficiency virus (SIV) viremia; however, CD8 + T cells that migrate to LT are primarily noncytotoxic, calling into question whether these cells could reduce the viral reservoir on antiretroviral therapy (ART) or control viral replication when therapy is halted. To determine whether CD8 + T cells can inhibit viral replication when retained in LT, we inhibited lymphocyte egress from LTs in ART-treated SIV-infected rhesus macaques (RMs) during analytic treatment interruption (ATI) using the S1PR modulator FTY720 alone or in combination with anti-PD1 antibody (αPD1) and the IL-15 receptor superagonist N-803 to increase cytolytic function. FTY720 retained migrating CD4 + and CD8 + T cells in LT, whereas cytotoxic CD8 + T cells remained in the vasculature. After ATI and viral rebound, activated SIV-specific CD8 + T cells increased in frequency in LT of FTY720-treated RMs but failed to become cytotoxic or control plasma viremia compared to controls, even when combined with αPD1 and N-803. These findings indicate that LT-localized CD8 + T cells alone may be insufficient to delay or prevent plasma viral rebound during ATI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
- Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104.
- Division of Microbiology and Immunology, Emory National Primate Research Center, Emory University, Atlanta, GA 30329.
- AIDS and Cancer Virus Program, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc., Frederick, MD 21701.
- Infection Analytics Program, Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, NSW 2033, Australia.
- ImmunityBio, Inc., Culver City, CA 90245.
ORCID-Profile: M Betina Pampena, Leticia Kuri-Cervantes, Steffen Docken, Brandon F Keele, Miles P Davenport, Michael R Betts
Förderung
- NIAID NIH HHS
- Tissue Reservoirs Scientific Working Group in the Penn Center for AIDS Research
- NCI NIH HHS
- NIH HHS
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
- HHS | NIH | National Cancer Institute (NCI)
- Center for AIDS Research at Emory University
Zitieren
APA
Pampena, M. B., Samer, S., Viox, E. G., Nguyen, K., Deleage, C., Kuri-Cervantes, L., Regan, J., Wu, V. H., Docken, S., Safrit, J. T., Bar, K. J., Keele, B. F., Davenport, M. P., Paiardini, M., & Betts, M. R. (2025). Therapeutic CD8 + T cell tissue retention and immunomodulation during ART interruption fail to prevent SIV rebound. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2501037122
Vancouver
Pampena MB, Samer S, Viox EG, Nguyen K, Deleage C, Kuri-Cervantes L, et al. Therapeutic CD8 + T cell tissue retention and immunomodulation during ART interruption fail to prevent SIV rebound. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2501037122
BibTeX
@article{Pampena2025,
author = {Pampena, M Betina and Samer, Sadia and Viox, Elise G and Nguyen, Kevin and Deleage, Claire and Kuri-Cervantes, Leticia and Regan, James and Wu, Vincent H and Docken, Steffen and Safrit, Jeffrey T and Bar, Katharine J and Keele, Brandon F and Davenport, Miles P and Paiardini, Mirko and Betts, Michael R},
title = {Therapeutic CD8 + T cell tissue retention and immunomodulation during ART interruption fail to prevent SIV rebound},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2501037122}
}
EUVIMED